JPRN-UMIN000009369招募中2 期
Randomized phase II study of zoledronate administration schedule comparing every 4 weeks versus every 8 weeks for metastatic lung cancer with bone metastasis - Zoledronate administration schedule P2 study
Institute of Biomedical Research and Innovation0 个研究点目标入组 210 人开始时间: 2012年11月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with a history of intravenous bisphosphonate therapy 2)Uncontrolled co-morbidities and/or infectious diseases 3)Women who are pregnant, have a desire to bear children or in lactation 4)Recent (within 4 weeks) tooth extraction due to dental infection 5)Planned dental or jaw surgery (e.g., extraction, implants) 6)Any other current malignancy or malignancy diagnosed within the past five years. 7)Patients deemed unacceptable for inclusion to the study.
研究者
相似试验
招募中
2 期
The LoPeZ studyMetastatic non-small cell lung carcinoma with bony metastasesCancer - Lung - Non small cellCancer - BoneACTRN12606000079549Peter MacCallum Cancer Centre14
已完成
不适用
A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study.Multiple MyelomaNL-OMON26780Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl407
已完成
2 期
Phase II study of zoledronic acid concomitant with androgen deprivation therapy for patients with treatment-naive bone-metastatic prostate cancerProstate cancerJPRN-UMIN000007548Kinki University52
进行中（未招募）
1 期
Short term biological study effects of Zoledronate and Letrozole on invasive breast cancer - Short term effects (preoperative) of Femara and Zometa or Femara aloneBreast CancerEUCTR2004-004223-36-GBSouth Manchester University Hospital110
进行中（未招募）
1 期
A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM) - zoledronic acid in myelofibrosismyelofibrosis with myeloid metaplasiaEUCTR2005-003985-40-BEDepartment of Internal Medicine, University Hospital Gasthuisberg16